Почетна › Прекумерна телесна тежина › Њујорк
Клинички испитувања за Прекумерна телесна тежина во Њујорк
45 студии за Прекумерна телесна тежина бараат учесници на локации во Њујорк.
Градови во Њујорк
- New York City19 студии
- Rochester13 студии
- Buffalo7 студии
- Syracuse4 студии
- Manhattan4 студии
- Cheektowaga4 студии
- Brooklyn3 студии
- Albany3 студии
- Queens3 студии
Официјален текст на студијата (англиски)
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Velocity Clinical Research- Binghamton, Binghamton
- Rochester Clinical Research, Rochester
Се регрутираФаза 3
Возраст од 18 до 99 · Сите полови · Ажурирано 5.10.2026 · NCT07684235Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Velocity Clinical Research - Binghamton, Binghamton
- Hudson Valley Cardiovascular Practice PC, Poughkeepsie
- Rochester Clinical Research, Rochester
- и уште 2
Се регрутираФаза 3
Возраст од 45 до 99 · Сите полови · Ажурирано 5.10.2026 · NCT07037433Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Rochester Clinical Research /ID# 282484, Rochester
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 2.10.2026 · NCT07752979Hydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy
- State University of New York at Buffalo, South Campus, Buffalo
Се регрутира
Возраст од 18 до 60 · Сите полови · Ажурирано 2.10.2026 · NCT07641361Comparing the Efficacy and Safety of the EndoZip System and Apollo ESG in Obese Patients
- Weill Cornell -1300 York Avenue, New York
- Lenox Hill Hospital | Northwell Health, New York
Се регрутира
Возраст од 21 до 65 · Сите полови · Ажурирано 1.10.2026 · NCT07090005A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- UBMD Physicians Group - Pediatrics - Conventus, Buffalo
- SUNY Upstate Medical Univ - Syracuse, Syracuse
- Advantage Clinical Trials, The Bronx
Се регрутираФаза 3
Возраст од 8 до 18 · Сите полови · Ажурирано 30.9.2026 · NCT07253285AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
- Southgate Medical Group, LLP, West Seneca
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 30.9.2026 · NCT07533175Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
- Rochester Clinical Research, Rochester
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 29.9.2026 · NCT07685808A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- Weill Cornell Medicine - Comprehensive Weight Control Center, New York
- Rochester Clinical Research, LLC, Rochester
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT07595549Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- ALSA Research-Manhattan, New York
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 28.9.2026 · NCT07837973A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Drug Trials America, Hartsdale
- NYC Research INC, Long Island City
- Rochester Clinical Research, LLC, Rochester
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT07794579A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
- Ichor Research, Syracuse
- Southgate Medical Group, LLP, West Seneca
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT07668414AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Comprehensive Weight Ctrl Prog, New York
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT07720271Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- New York Gastroenterology Associates, New York
- Care Access - Yonkers, Yonkers
Се регрутираФаза 3
Возраст од 18 до 70 · Сите полови · Ажурирано 24.9.2026 · NCT06937099A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- UBMD Pediatrics, Buffalo
Се регрутираФаза 3
Возраст од 6 до 17 · Сите полови · Ажурирано 24.9.2026 · NCT06672549Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Icahn School of Medicine at Mount Sinai, New York
- New York Gastroenterology Associates, New York
- Care Access - Yonkers, Yonkers
Се регрутираФаза 3
Возраст од 18 до 70 · Сите полови · Ажурирано 24.9.2026 · NCT06937086A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- NYU Langone Health, New York
- Weill Cornell Medical College, New York
- IMA Clinical Research Manhattan, New York
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07392190A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- NYC Research INC, Long Island City
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07282600Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Ellipsis Research Group - Brooklyn - 7th Street, Brooklyn
- Rochester Clinical Research - Buffalo, Buffalo
- NYC Research INC, Long Island City
- и уште 1
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07353931A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Dent Neurologic Institute, Amherst
- Rochester Clinical Research, LLC, Rochester
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 22.9.2026 · NCT07589608A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- Rochester Clinical Research - Buffalo, Buffalo
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07369011A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- Rochester Clinical Research, LLC, Rochester
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07321886A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, East Northport
- AURORA-2 Clinical Site, East Syracuse
- AURORA-2 Clinical Site, New Windsor
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 16.9.2026 · NCT07743450A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, New Windsor
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 16.9.2026 · NCT07743463A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- NYC Research INC, Long Island City
- Richmond University Medical Center, Staten Island
- Southgate Medical Group, West Seneca
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 14.9.2026 · NCT06897475A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Rochester Clinical Research, Buffalo
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 14.9.2026 · NCT07351045A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Albany
- ACCOMPLISH-2 Research Site, Albany
- ACCOMPLISH-2 Research Site, Brooklyn
- и уште 1
Се регрутираФаза 3Добредојдени се здрави волонтери
Возраст од 18 до 79 · Сите полови · Ажурирано 11.9.2026 · NCT07654374AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
- Weil Cornell Medicine, New York
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 11.9.2026 · NCT07571005AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
- Weil Cornell Medicine, New York
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 9.9.2026 · NCT07571109A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Dent Neurologic Institute, Amherst
- Velocity Clinical Research, Syracuse, East Syracuse
- Rochester Clinical Research, LLC, Rochester
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 8.9.2026 · NCT06143956A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Equity Medical, New York
Се регрутираФаза 4
Возраст 18 и постари · Сите полови · Ажурирано 4.9.2026 · NCT06857942Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Albany
- Kailera Clinical Site, Laurelton
- Kailera Clinical Site, New York
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 3.9.2026 · NCT07284901Alpelisib Challenge Test (ACT)
- Columbia University Irving Medical Center, New York
Се регрутираФаза 1Добредојдени се здрави волонтери
Возраст од 18 до 70 · Сите полови · Ажурирано 3.9.2026 · NCT07778524Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Rochester
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 3.9.2026 · NCT07284875Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)
- Mexican Consulate's Ventanilla de Salud (VDS), New York
Се регрутираФаза 2Добредојдени се здрави волонтери
Возраст 21 и постари · Сите полови · Ажурирано 2.9.2026 · NCT05770570Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Icahn School of Medicine at Mount Sinai, New York
- Rochester Clinical Research, Rochester
Се регрутираФаза 3
Возраст од 18 до 99 · Сите полови · Ажурирано 27.8.2026 · NCT07575399A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Cortland
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.8.2026 · NCT07784725Human Models of Selective Insulin Resistance: Alpelisib, Part I
- Columbia University Irving Medical Center, New York
Се регрутираФаза 1Добредојдени се здрави волонтери
Возраст од 18 до 70 · Сите полови · Ажурирано 24.8.2026 · NCT06354088AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- NYU Langone Orthopedic Center, New York
- Hospital For Special Surgery, New York
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 17.8.2026 · NCT07509307Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Albany
- ACCOMPLISH-1 Research Site, Brooklyn
Се регрутираФаза 3
Возраст од 18 до 79 · Сите полови · Ажурирано 10.8.2026 · NCT07654361Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.